Eplerenone ( DrugBank: Eplerenone )


4 diseases
IDDisease name (Link within this page)Number of trials
75Cushing disease1
113Muscular dystrophy2
210Single Ventricle1
215Tetralogy of Fallot1

75. Cushing disease


Clinical trials : 205 Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000002925
2009/12/0128/12/2009Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension. - A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy. Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.50mg of Eplerenone monotherapy once daily for 6 weeks on subclinical Cushing's syndrome
80mg of Valsartan monotherapy once daily for 6 weeks on subclinical Cushing's syndrome
50mg of Eplerenone monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma
80mg of Valsartan monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma
Hiroshima University HospitalDepartment of Endocrinology and Diabetes mellitusNULLComplete: follow-up complete20years-oldNot applicableMale and Female80Not selectedJapan

113. Muscular dystrophy


Clinical trials : 646 Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02354352
(ClinicalTrials.gov)
March 20, 201527/1/2015Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyTherapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: Eplerenone;Drug: SpironolactoneOhio State UniversityUniversity of California, Los Angeles;University of Utah;University of Colorado, Denver;University of Kansas Medical Center;Vanderbilt University Medical CenterCompleted7 YearsN/AMale52Phase 3United States
2NCT01521546
(ClinicalTrials.gov)
February 201226/1/2012Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular DystrophyEarly Treatment With Aldosterone Antagonism Attenuates Cardiomyopathy in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: eplerenone;Drug: placeboSubha RamanBallou SkiesCompleted7 YearsN/AMale42N/AUnited States

210. Single Ventricle


Clinical trials : 51 Drugs : 53 - (DrugBank : 22) / Drug target genes : 32 - Drug target pathways : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01971593
(ClinicalTrials.gov)
August 201323/10/2013The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart DiseaseEplerenone to Prevent Myocardial Fibrosis in Congenital Heart DiseaseTetralogy of Fallot;Transposition of the Great Vessels With an Arterial Switch;Single Ventricle With a Fontan PalliationDrug: EplerenoneWashington University School of MedicinePfizerTerminated18 Years80 YearsAll26Phase 4United States

215. Tetralogy of Fallot


Clinical trials : 18 Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01971593
(ClinicalTrials.gov)
August 201323/10/2013The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart DiseaseEplerenone to Prevent Myocardial Fibrosis in Congenital Heart DiseaseTetralogy of Fallot;Transposition of the Great Vessels With an Arterial Switch;Single Ventricle With a Fontan PalliationDrug: EplerenoneWashington University School of MedicinePfizerTerminated18 Years80 YearsAll26Phase 4United States